Stifel analyst Thomas Stephan resumed coverage of Globus Medical (GMED) with a Hold rating and $64 price target Respondents in the firm’s spine surgeon survey expect moderating 2026 spine procedure growth and as an industry leader, Globus would likely be among the most susceptible to any market softness, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED: